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Acute panmyelosis with myeloﬁbrosis (APMF) is a rare, fatal hematological neoplasm that is characterized by the acute onset of
cytopenias andﬁbrosis in the bone marrowin the absence ofsplenomegalyor ﬁbrosis-related morphologicalchanges inthe RBCs.
We present the case of a 59-year-old female who presented with a two-month history of anemia, leucopenia and a normal platelet
count. The marrow was heavily ﬁbrotic, and no aspirate material could be obtained; the biopsy showed extensive inﬁltration with
small to medium size megakaryocytes, dysplastic changes in the erythroid compartment, and left shift in the myeloid cells. The
patient was treated for four months with anabolic steroids (Danazol), growth factors and received regular blood transfusions.
At 4 months after diagnosis, the patient was started on Lenalidomide, 10mg/day for a 21-d-course along with growth factor
support. At 6 months after treatment, the patient was transfusion-independent, had normalized blood counts, and, at 32 months
on continuous lenalidomide treatment, her needs for growth factor support have been minimized. Repeat bone marrow biopsies
showed a patchy distribution of ﬁbrosis with areas of normal cellularity and morphology. To our knowledge, this is the ﬁrst case
for a medication that could reverse the fatal outcome of APMF.
1.Introduction
Acute panmyelosis with myeloﬁbrosis (APMF) is a rare
disease entity that was initially described as “malignant mye-
losclerosis” [1] almost 50 years ago. In the recent WHO clas-
siﬁcation, the term acute panmyelosis with myeloﬁbrosis
(APMF, ICD-O code 9931/3) has been coined to describe
an identical clinical syndrome characterized by constitu-
tional symptoms, cytopenias, absence of splenomegaly and
of related morphological changes in the RBCs; the disorder
runs a rapid and usually fatal course. Histologically, APMF
is characterized by a heavily ﬁbrotic marrow, an increased
cellularity with the presence ofimmature precursors from all
three lineages (panmyelosis), and an abnormal population
of megakaryocytes [2]. The latter show dysplastic features
with under- or nonlobulated nuclei, dispersed chromatin,
and a high proportion of small-sized cells. The condition
shouldbediﬀerentiatedfromotherhematologicalneoplasms
that present with ﬁbrosis such as acute megakaryoblastic
leukemia and MDS with ﬁbrosis; in the former, the presence
of more than 20% blasts with at least half of them expressing
megakaryocyte markers conﬁrms the diagnosis, while, in the
latter, the distinction is based on the subacute onset and the
presence of dysplastic features characteristic of MDS. At the
clinical level, APMF is characterized by rapid progression
and a fatal outcome usually within months from diagnosis;
in a relatively large series of 46 patients, 76% succumbed
to severe bone marrow failure, and 22% developed acute
myeloid leukemia [3].
One medication that has therapeutic potential in MDS
with the 5q-karyotype and marginal eﬃcacy in myeloﬁbrosis
is lenalidomide [4, 5]. A feature of the 5q-MDS is the
increased number of megakaryocytes with no ﬁbrosis in
the bone marrow. The precise mechanism of lenalidomide’s
action isuncertain since ithaspleiotropiceﬀectsand belongs
to a new generation of drugs known as immunomodulatory2 Case Reports in Medicine
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Figure 1: (a, b, c) relatively hypercellular marrow with marked
ﬁbrosis, abundant atypical megakaryocytes, and scattered imma-
ture-appearing cells, (a, b) H&E-stained sections, (c) reticulin
stain). (d, e, f) following treatment with lenalidomide, the bone
marrow showed patchy hematopoiesis with areas of high and low
cellularity ((d) H&E-stained section), decreased numbers of meg-
akaryocytes ((e) H&E-stained section) and a marked reduction in
reticulin ﬁbrosis ((f) reticulin stain).
(IMiDs). However, there is evidence that lenalidomide has
antiproliferative potential on the MDS clone, can alter the
T- and NK-cell responses, can downregulate cytokine
expression, and has an eﬀect on vascular proliferation by
modulating VEGF expression [6]. A common side eﬀect
of lenalidomide treatment is reversible thrombocytopenia
indicating that the formulation may have a speciﬁc, yet
unidentiﬁed, action on megakaryocyte proliferation. Based
on this hypothesis and on the conﬁrmed action of lenalido-
mide in the 5q-MDS and in primary myeloﬁbrosis, we
sought to investigate its potential for the treatment of APMF.
2.CaseReport
A 59-year-old female was referred to our unit for the
investigation of anemia; the patient complained of fatigue
and malaise that started about one month prior to her visit.
Shedidnotmentionanyotherconstitutionalsymptomssuch
as fever or weight loss. Her past medical history revealed
that she had mild mitral and aortic valve insuﬃciency along
with atrial ﬁbrillation and was on digitalis, an ACE inhibitor
and acenocoumarol with a target INR of 2.5. On physical
examination, she was pale, afebrile, had no palpable lymph
nodes, and her abdomen did not disclose any organomegaly.
Her CBC showed severe anemia with a hemoglobin level
of 7.2g/dL, an MCV of 94.8fL, leucopenia (3400/uL, with
ad i ﬀerential of 56% PMN, 38% lymphocytes, 5% mononu-
clears, and 1% eosinophils). The platelet count was elevated
(756,000/uL), and some giant forms could be observed
in the smear. Microscopic examination of the peripheral
blood did not show any abnormalities associated with
myeloﬁbrosis, while the WBC had no dysplastic features.
Serum parameters were normal except for ferritin (12 × the
upper limit of normal, ULN) and LDH (1.8 × the ULN).
Bone marrow aspiration did not yield any material, and it
was considered as “dry tap.” Pathology revealed increased
cellularity and ﬁbrosis; there was prominent hyperplasia of
the megakaryocytic lineage with clustering and dysplastic
features (Figures 1(a) to 1(c)). Few (less than 5%) small
sized CD61 positive cells with prominent nucleoli were also
observed which however did not express CD34. Hyperplasia
was also noted in the myeloid lineage with a left shift and
a normal blast count; the erythroid lineage was propor-
tionally diminished. Molecular analysis for bcr-abl and
JAK2V617F mutation were negative. Based on the available
ﬁndings, the acute onset, and the absence of splenomegaly,
the diagnosis of primary myeloﬁbrosis was excluded; the
picturewasconsistentwith eitheracaseofacutemyeloﬁbrosi
or a secondary ﬁbrosis accompanying either an atypical
myeloproliferative disorder or an MDS. The possibility of
reactive ﬁbrosis secondary to an inﬁltration of malignant
cells was excluded based on negative clinical, radiological,
and histochemical ﬁndings.
The patient was transfused regularly and was started on
ESAs (epoetin alfa, 40.000iu per week) and oral danazol
(200mgqd). At two months following her admission, she
was still transfusion-dependent, and her blood counts were
deteriorating, her hemoglobin level was at 6.5gr/dL, her
WBCs were at 3,400/uL with normal diﬀerential and the
platelets were at 224,000/uL. A repeat bone marrow was
performed at 5 months after presentation with an identical
picture on the biopsy; the marrow was still a “dry tap,” but,
ofthefew progenitors,akaryotypewasobtainedthatshowed
a normal 46; XX chromosomal pattern. A marginal increase
in the myeloid blasts was also noted, but the overall number
of CD34+/cKit+ cells was less than 3%.
At this point, a decision was made to withhold danazol
and start on lenalidomide at a dose of 10mgqd for 21
days of 28 days cycles, while growth factor support was
maintained. The patient tolerated the therapy well, and,
within 3 months, her transfusion requirements subsided,
and she experienced a gradual increase in her hemoglobin
levelsthatreached15gr/dLatthe10thmonthlylenalidomide
cycle. At this point, her WBC count and diﬀerential were
normal, and she had consistently lower than normal PLT
levels (135,000/uL on average); growth factor support with
ESA and G-CSF has continued, but the needs have been
cut to half. A repeat bone marrow was performed at the
18th cycle of lenalidomide which for the ﬁrst time showed
a patchy distribution of cellularity; however, in areas of
high cellularity, an identical clustering of the abnormal
megakaryocytes could be observed (Figures 1(c) to 1(d)). Of
the other lineages, the erythroid showed dysplastic features,Case Reports in Medicine 3
Table 1: The basic characteristics that help in the diﬀerential diag-
nosis of APMF (acute panmyelosis with myeloﬁbrosis), PMF
(primary myeloﬁbrosis), and the 5q-syndrome according to the
recent WHO classiﬁcation(2008).
APMF PMF 5q-
MGK increase Prominent Present Present
JAK2V617F No Yes (50%) No
Acute onset Yes No No
Splenomegaly No Yes No
Marrow Fibrosis Yes Yes No
Pancytopenia Yes No No
while, in the myeloid compartment, a marginally elevated
number of immature cells was recorded (4%-5% blasts of
myeloid lineage).
Currently, at almost three years after her initial admis-
sion, the patient has stabilized her counts requiring ESA
every21daysand GCSFeveryotherweek.Nomorphological
changes can be observed in her peripheral blood, and no
splenomegaly has developed.
3.Discussion
Acute myeloﬁbrosis refers to a number of disorders that
present with cytopenias, absence of splenomegaly, and
a clinical course of fatal peripheral blood insuﬃciencies or
the development of leukemias. A number of disease entities
could present with such a picture such as acute panmyelosis
with myeloﬁbrosis (APMF), MDS with ﬁbrosis, AML of the
M7 subtype, and unspeciﬁed myeloproliferative neoplasms
with ﬁbrosis. Our patient ﬁlled the criteria of APMF as
speciﬁed in the new WHO listing of hematological neo-
plasms [2]; the patient had a typical clinical course, had no
morphological abnormalities in the peripheral blood, and
no splenomegaly, no megakaryoblasts but an abundant inﬁl-
tration of abnormal megakaryocytes (MGK) and reticulin
deposition in the bone marrow. According to what has been
previously published [3], a prominent feature of APMF that
was also present in our patient is the presence of MGK
clusters (32% of cases) and microMGK with maturation
defects (96% of cases). Of the other disease features, the sole
unique abnormality in our patient was an elevated platelet
count at presentation that later fell below normal levels and
normalized after the 3rd course of lenalidomide.In addition,
we could not conﬁrm any other cause of reactive ﬁbrosis
since neither digitalis, ACE inhibitors, nor acenocoumarol
has been linked to myeloﬁbrosis. The possibility that our
patient was an atypical case of a 5q-MDS cannot be
supported based on a normal karyotype, lack of dysplastic
features in the peripheral, and presence of reticulin ﬁbrosis.
However, APMF cases with partial loss of 5q have been
observed in one series [7], while aberrations of chromosome
7 were recorded in a signiﬁcant number of cases usually as
part of a complex karyotype. The distinction to the classical
primary myeloﬁbrosis (PMF) is relatively straightforward; a
brief outline of the major features that characterize APMF,
PMF, and the 5q-syndrome are presented in Table 1.
T h eb o n em a r r o wi nt h ep u b l i s h e dA P M Fs e r i e si s
consistentlyinaspirable;incaseswheremetaphaseshavebeen
obtained [7], a partial loss of 5q has been described, either
as the sole abnormality or as along with other abnormalities
such as monosomy 7 and trisomy 8. These chromosomal
aberrations are consistent with an aggressive myeloid neo-
plasm which however culminates in AML only in a minority
of cases. In our patient, we could only analyze one sample
that was obtained after 15 months on lenalidomide; of the
7 metaphases, all had a normal female karyotype. Although
normal karyotypes in APMF have been described, the
possibility remains that the abnormal clone may be extinct
due to lenalidomide treatment.
APMF is a rare disease entity accounting for less than 1%
of all hematological neoplasms and has a fatal course usually
within months from diagnosis. In a series of 46 patients [3],
76% of patients succumbed to hemorrhage or infections,
and 22% developed AML, while the median survival was
9 months. This dismal prognosis has been reverted in our
patient with the administration of lenalidomide that had
an impact on both the clinical picture and the BM ﬁbrosis.
The exact action of lenalidomide is still unknown, but it has
immunomodulatory, antiangiogenic, and direct antitumor
eﬀects mediated by an increase in Th1 cytokines and NK cell
activity [6]. Inthecase ofAPMF,thepathogenesis isobscure,
but alterations in the BM vasculature, the cytokine network,
and the immunological milieu have all been described [3].
The documented eﬃciency of lenalidomide in the treatment
of the 5q-MDS and in our case study cannot be attributed to
any speciﬁc component of its pleiotropic actions.
The pathogenesis of APMF is unknown, and the rarity of
the disease makes its study a medical challenge. Mutationsin
the JAK-STAT kinase pathway or the MPL receptor have not
beenrecorded,andthereisnospeciﬁccytogeneticabnormal-
ity; however, there is a predilection for complex karyotypes
involving both chromosomes 5 and 7, similar to MDS and
acute leukemias. In the series of 46 patients, exposure to
a toxicagentwas identiﬁedin3patients[3],while inourcase
we could not identify any oﬀending agent; our patient was
notoccupiedandwouldonlyoccasionallyhelpherhusband’s
farming activities. A recurring feature in all patients with
APMF is the presence of abnormalities particularly in the
megakaryocytes, which have been implicated in the devel-
opment of idiopathic myeloﬁbrosis [8]. In the latter, MKs
are produced in higher rates by the abnormal HSC clone,
and they produce large amounts of TGFb, a cytokine that
playsacrucialroleinthedevelopmentofmarrowﬁbrosis[9].
In addition, TGFb upregulates osteoprotegerin expression
which in turn inhibits osteoclasts and results in the increased
deposition of extracellular matrix in eﬀect altering the bone
marrow microenvironment.
There are no consensus standards for the treatment
of APMF. A variety of therapeutic strategies have been
employed without success. Nontoxic agents such as zole-
dronic acid and danazol have produced remissions, while
a single case of autologous stem cell transplantation has
been reported [10] that resulted in 9 years of remission.
Thalidomide and its analog lenalidomide are antiangio-
genic and immunomodulatory agents that inhibit several4 Case Reports in Medicine
proinﬂammatory cytokines. They also have direct antitumor
activity in myeloma and myelodysplastic cell lines. Their use
in patient with idiopathic myeloﬁbrosis has been marginally
successful [5], while lenalidomide has been approved for the
MDS 5q-disorder. We used lenalidomide in our patient on
the basis of its beneﬁcial eﬀect in patients with idiopathic
myeloﬁbrosis and the 5q-syndrome. Currently, at almost 3
years on continuous lenalidomide treatment, we started an
alternate month administration scheme and have further
reduced growth factor support. Although lenalidomide’s
actionin APMF has not beenreported before, if replicated in
other cases, it could provide a treatment option for a lethal
disorder.
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